Lyndsay N. Harris

24.4k total citations · 7 hit papers
192 papers, 15.0k citations indexed

About

Lyndsay N. Harris is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Lyndsay N. Harris has authored 192 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 79 papers in Cancer Research and 68 papers in Molecular Biology. Recurrent topics in Lyndsay N. Harris's work include HER2/EGFR in Cancer Research (76 papers), Breast Cancer Treatment Studies (44 papers) and Cancer Treatment and Pharmacology (36 papers). Lyndsay N. Harris is often cited by papers focused on HER2/EGFR in Cancer Research (76 papers), Breast Cancer Treatment Studies (44 papers) and Cancer Treatment and Pharmacology (36 papers). Lyndsay N. Harris collaborates with scholars based in United States, Germany and China. Lyndsay N. Harris's co-authors include Daniel F. Hayes, Eric P. Winer, Robert Mennel, Robert C. Bast, Larry Norton, Mark R. Somerfield, Sheila E. Taube, Peter M. Ravdin, Herbert A. Fritsche and Zoltán Szállási and has published in prestigious journals such as Cell, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Lyndsay N. Harris

178 papers receiving 14.6k citations

Hit Papers

American Society of Clinical Oncology 2007 Update of Reco... 2002 2026 2010 2018 2007 2002 2006 2006 2016 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
    2007 1.7k citations Lyndsay N. Harris, Robert Mennel et al. Journal of Clinical Oncology profile →
  2. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 1.5k citations Charles L. Vogel, Lyndsay N. Harris et al. Journal of Clinical Oncology profile →
  3. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
    2006 874 citations Lyndsay N. Harris et al. Journal of Clinical Oncology profile →
  4. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
    2006 854 citations Lyndsay N. Harris et al. profile →
  5. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    2016 576 citations Lyndsay N. Harris, Nofisat Ismaila et al. Journal of Clinical Oncology profile →
  6. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
    2003 554 citations Harold J. Burstein, Lyndsay N. Harris et al. profile →
  7. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancer
    2019 235 citations William M. Sikov, Lyndsay N. Harris et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lyndsay N. Harris United States 53 9.3k 5.5k 5.1k 3.0k 2.9k 192 15.0k
Aňa Lluch Spain 55 10.3k 1.1× 6.1k 1.1× 4.1k 0.8× 2.7k 0.9× 2.5k 0.9× 306 14.7k
Francisco J. Esteva United States 68 11.6k 1.2× 4.6k 0.8× 7.0k 1.4× 4.9k 1.6× 3.2k 1.1× 280 18.0k
P. Fumoleau France 61 9.6k 1.0× 4.4k 0.8× 3.3k 0.6× 2.3k 0.8× 2.7k 0.9× 326 14.3k
Brian Leyland‐Jones United States 53 11.6k 1.2× 4.6k 0.8× 5.7k 1.1× 4.1k 1.4× 3.3k 1.2× 218 18.4k
John M.S. Bartlett United Kingdom 60 10.5k 1.1× 7.0k 1.3× 6.2k 1.2× 4.1k 1.4× 3.7k 1.3× 310 18.8k
Sabino De Placido Italy 64 7.8k 0.8× 3.7k 0.7× 4.4k 0.8× 1.6k 0.6× 4.5k 1.6× 381 14.0k
Wedad Hanna Canada 45 10.6k 1.1× 7.6k 1.4× 4.6k 0.9× 3.5k 1.2× 3.2k 1.1× 156 17.0k
Joan Albanell Spain 56 7.9k 0.9× 3.0k 0.5× 4.8k 0.9× 2.4k 0.8× 2.9k 1.0× 251 12.6k
Aleix Prat Spain 55 8.9k 1.0× 6.1k 1.1× 5.8k 1.1× 1.3k 0.4× 3.5k 1.2× 395 14.7k
Aditya Bardia United States 58 10.9k 1.2× 5.0k 0.9× 4.0k 0.8× 1.8k 0.6× 5.4k 1.9× 481 16.1k

Countries citing papers authored by Lyndsay N. Harris

Since Specialization
Citations

This map shows the geographic impact of Lyndsay N. Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lyndsay N. Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lyndsay N. Harris more than expected).

Fields of papers citing papers by Lyndsay N. Harris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lyndsay N. Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lyndsay N. Harris. The network helps show where Lyndsay N. Harris may publish in the future.

Co-authorship network of co-authors of Lyndsay N. Harris

This figure shows the co-authorship network connecting the top 25 collaborators of Lyndsay N. Harris. A scholar is included among the top collaborators of Lyndsay N. Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lyndsay N. Harris. Lyndsay N. Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Skarlupka, Amanda L., Christos Patriotis, Wendy S. Rubinstein, et al.. (2025). Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study. Cancer Epidemiology Biomarkers & Prevention. 34(10). 1787–1793.
2.
Gouda, Mohamed A., Filip Jankú, Ying Yuan, et al.. (2025). Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research. 31(20). 4299–4310. 1 indexed citations
3.
O’Hara, Mark H., Opeyemi A. Jegede, Mark A. Dickson, et al.. (2024). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical Cancer Research. 31(1). 56–64. 1 indexed citations
4.
Minasian, Lori M., Paul F. Pinsky, Hormuzd A. Katki, et al.. (2022). Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. JNCI Journal of the National Cancer Institute. 115(3). 250–257. 36 indexed citations
5.
Harris, Lyndsay N., Nofisat Ismaila, Lisa M. McShane, et al.. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 34(10). 1134–1150. 576 indexed citations breakdown →
6.
Merry, Callie R., Sarah McMahon, Cheryl L. Thompson, et al.. (2015). Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer. Breast Cancer Research and Treatment. 150(2). 321–334. 16 indexed citations
7.
Varadan, Vinay, Sitharthan Kamalakaran, Hannah Gilmore, et al.. (2015). Brief‐exposure to preoperative bevacizumab reveals a TGF‐β signature predictive of response in HER2‐negative breast cancers. International Journal of Cancer. 138(3). 747–757. 14 indexed citations
8.
Mayer, Erica L., Lyndsay N. Harris, Julie Gold, et al.. (2014). Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer. Clinical Breast Cancer. 15(1). 24–30. 11 indexed citations
9.
Dueck, Amylou C., Monica M. Reinholz, Xochiquetzal J. Geiger, et al.. (2013). Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. Clinical Cancer Research. 19(20). 5798–5807. 19 indexed citations
10.
Perez, Edith A., Monica M. Reinholz, David W. Hillman, et al.. (2010). HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 28(28). 4307–4315. 176 indexed citations
11.
12.
Alexe, Gabriela, Gul S. Dalgin, Daniel Scanfeld, et al.. (2007). High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. Cancer Research. 67(22). 10669–10676. 166 indexed citations
13.
Shi, Qian, Lyndsay N. Harris, X. Lucas Lu, et al.. (2006). Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery. Journal of Proteome Research. 5(11). 2947–2955. 34 indexed citations
14.
Harris, Lyndsay N., Gloria Broadwater, Nancy U. Lin, et al.. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research. 8(6). 123 indexed citations
15.
16.
Bentires‐Alj, Mohamed, Susana G. Gil, Richard Chan, et al.. (2005). A role for the scaffolding adapter GAB2 in breast cancer. Nature Medicine. 12(1). 114–121. 159 indexed citations
17.
Blackwell, Kimberly, Mark W. Dewhirst, Vlayka Liotcheva, et al.. (2004). HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors. Clinical Cancer Research. 10(12). 4083–4088. 61 indexed citations
18.
19.
Harris, Lyndsay N., Diana Lüftner, W. Jäger, & John F. R. Robertson. (1999). C-erbB-2 in Serum of Patients with Breast Cancer. The International Journal of Biological Markers. 14(1). 8–15. 33 indexed citations
20.
Lupu, Ruth, Marina Cardillo, Lyndsay N. Harris, et al.. (1996). The significance ofheregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research and Treatment. 38(1). 57–66. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aňa Lluch Breakdown of academic impact, for papers by Francisco J. Esteva Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Brian Leyland‐Jones Breakdown of academic impact, for papers by John M.S. Bartlett Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Wedad Hanna Breakdown of academic impact, for papers by Joan Albanell Breakdown of academic impact, for papers by Aleix Prat Breakdown of academic impact, for papers by Aditya Bardia
Rankless by CCL
2026